Pharmacokinetics of meropenem during intermittent and continuous intravenous application in patients treated by continuous renal replacement therapy

Intensive Care Medicine

Volumn 34, Issue 6, 2008, Pages 1091-1096

  Langgartner, Julia ^a   Vasold, Antje ^a   Glück, Thomas ^b   Reng, Michel ^c   Kees, Frieder ^a  

^a UNIVERSITY OF REGENSBURG   (Germany)

^b General Hospital Traunstein   (Germany)

^c General Hospital Bogen   (Germany)

Author keywords

Beta lactam antibiotics; Continuous infusion; CVVHD; Meropenem; Pharmacodynamics; Pharmacokinetics; Renal replacement therapy

Indexed keywords

MEROPENEM;

ACUTE PANCREATITIS; ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTINUOUS HEMODIALYSIS; CONTINUOUS RENAL REPLACEMENT THERAPY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG HALF LIFE; FEMALE; HUMAN; INTENSIVE CARE UNIT; KIDNEY FAILURE; MALE; MINIMUM INHIBITORY CONCENTRATION; PNEUMONIA; RANDOMIZED CONTROLLED TRIAL; SEPSIS;

ADULT; AGED; ANTI-BACTERIAL AGENTS; AREA UNDER CURVE; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CROSS-OVER STUDIES; FEMALE; HUMANS; INTENSIVE CARE UNITS; LEAST-SQUARES ANALYSIS; MALE; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; PROSPECTIVE STUDIES; RENAL REPLACEMENT THERAPY; THIENAMYCINS;

EID: 46149116065     PISSN: 03424642     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00134-008-1034-7     Document Type: Article

References (24)

1. Craig WA, Ebert SC (1990) Killing and regrowth of bacteria in vitro: a review. Scand J Infect Dis Suppl 74:63-70
2. Craig WA, Ebert SC (1992) Continuous infusion of beta-lactam antibiotics. Antimicrob Agents Chemother 36:2577-2583
3. Turnidge JD (1998) The pharmacodynamics of beta-lactams. Clin Infect Dis 27:10-22
4. Vogelman B, Craig WA (1986) Kinetics of antimicrobial activity. J Pediatr 108:835-840
5. Craig WA (1998) Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men. Clin Infect Dis 26:1-10; quiz 11-12
6. Nicolau DP (2001) Predicting antibacterial response from pharmacodynamic and pharmacokinetic profiles. Infection 29 Suppl 2:11-15
7. Nicolau DP, Nightingale CH, Banevicius MA, Fu Q, Quintiliani R (1996) Serum bactericidal activity of ceftazidime: continuous infusion versus intermittent injections. Antimicrob Agents Chemother 40:61-64
8. Elkhaili H, Niedergang S, Pompei D, Linger L, Leveque D, Jehl F (1996) High-performance liquid chromatographic assay for meropenem in serum. J Chromatogr B 686:19-26
9. Jaruratanasirikul S, Sriwiriyajan S (2003) Stability of meropenem in normal saline solution after storage at room temperature. Southeast Asian J Trop Med Public Health 34:627-629
10. Takeuchi Y, Takebayashi Y, Sunagawa M, Isobe Y, Hamazume Y, Uemura A, Noguchi T (1993) The stability of a novel carbapenem antibiotic, meropenem (SM-7338), in a solid state formulation for injection. Chem Pharm Bull (Tokyo) 41:1998-2002
11. Patel PR, Cook SE (1997) Stability of meropenem in intravenous solutions. Am J Health Syst Pharm 54:412-421
12. Kuti JL, Nightingale CH, Knauft RF Nicolau DP (2004) Pharmacokinetic properties and stability of continuous-infusion meropenem in adults with cystic fibrosis. Clin Ther 26:493-501
13. Viaene E, Chanteux H, Servais H, Mingeot-Leclercq MP, Tulkens PM (2002) Comparative stability studies of antipseudomonal beta-lactams for potential administration through portable elastomeric pumps (home therapy for cystic fibrosis patients) and motor-operated syringes (intensive care units). Antimicrob Agents Chemother 46:2327-2332
14. Ververs TF, van Dijk A, Vinks SA, Blankestijn PJ, Savelkoul JF, Meulenbelt J, Boereboom FT (2000) Pharmacokinetics and dosing regimen of meropenem in critically ill patients receiving continuous venovenous hemofiltration. Crit Care Med 28:3412-3416
15. Valtonen M, Tiula E, Backman JT, Neuvonen PJ (2000) Elimination of meropenem during continuous veno-venous haemofiltration and haemodiafiltration in patients with acute renal failure. J Antimicrob Chemother 45:701-704
16. Krueger WA, Neeser G, Schuster H, Schroeder TH, Hoffmann E, Heininger A, Dieterich HJ, Forst H, Unertl KE (2003) Correlation of meropenem plasma levels with pharmacodynamic requirements in critically ill patients receiving continuous veno-venous hemofiltration. Chemotherapy 49:280-286
17. Thalhammer F, Traunmuller F, El Menyawi I, Frass M, Hollenstein UM, Locker GJ, Stoiser B, Staudinger T, Thalhammer-Scherrer R, Burgmann H (1999) Continuous infusion versus intermittent administration of meropenem in critically ill patients. J Antimicrob Chemother 43:523-527
18. Tegeder I, Neumann F, Bremer F, Brune K, Lötsch J, Geisslinger G (1999) Pharmacokinetics of meropenem in critically ill patients with acute renal failure undergoing continuous venovenous hemofiltration. Clin Pharmacol Ther 65:50-57
19. Thalhammer F, Schenk P, Burgmann H, El Menyawi I, Hollenstein UM, Rosenkranz AR, Sunder-Plassmann G, Breyer S, Ratheiser K (1998) Single-dose pharmacokinetics of meropenem during continuous venovenous hemofiltration. Antimicrob Agents Chemother 42:2417-2420
20. Krueger WA, Schroeder TH, Hutchison M, Hoffmann E, Dieterich HJ, Heininger A, Erley C, Wehrle A, Unertl K (1998) Pharmacokinetics of meropenem in critically ill patients with acute renal failure treated by continuous hemodiafiltration. Antimicrob Agents Chemother 42:2421-2424
21. Giles LJ, Jennings AC, Thomson AH, Creed G, Beale RJ, McLuckie A (2000) Pharmacokinetics of meropenem in intensive care unit patients receiving continuous veno-venous hemofiltration or hemodiafiltration. Crit Care Med 28:632-637
22. Meyer MM, Munar MY, Kohlhepp SJ, Bryant RE (1999) Meropenem pharmacokinetics in a patient with multiorgan failure from meningococcemia undergoing continuous venovenous hemodiafiltration. Am J Kidney Dis 33:790-795
23. Kuti JL, Nicolau DP (2005) Derivation of meropenem dosage in patients receiving continuous veno-venous hemofiltration based on pharmacodynamic target attainment. Chemotherapy 51:211-216
24. Robatel C, Decosterd L A, Biollaz J, Eckert P, Schaller MD, Buclin T (2003) Pharmacokinetics and dosage adaptation of meropenem during continuous venovenous hemodiafiltration in critically ill patients. J Clin Pharmacol 43:1329-1340